Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 20/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635560 | 1.00 | CSNK2A2 (1.00) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634975 | 1.00 | CSNK2A2 (1.00) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635052 | 0.93 | CSNK2A2 (0.87) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634855 | 0.93 | CSNK2A2 (0.87) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634853 | 0.93 | CSNK2A2 (0.87) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634802 | 0.93 | CSNK2A2 (0.87) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634805 | 0.93 | CSNK2A2 (0.87) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634720 | 0.91 | CSNK2A2 (0.84) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635235 | 0.91 | CSNK2A2 (0.84) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635230 | 0.91 | CSNK2A2 (0.84) | CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | CSNK2A2 123/4885CSNK2A1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.